Pharmaceutical Preparations · SAN DIEGO, CA, United States
$18.25
-5.49% (-$1.06)2026-10-02
Smart-Money SignalAccumulation · 62/100— Insiders are net buyers over 90 days ($33.3M, 5 buys vs 0 sales)
Price Performance
Historical data including institutional events
Company Profile
Z
Zhen Li
CEO & Executive Director
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-Ã precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimerâs disease. The company was incorporated in 2019 and is based in San Diego, California.
- Founded
- 2019
- Employees
- 50
- Headquarters
- SAN DIEGO, CA, United States
- Website
- www.adarx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...